Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Redhill Biopharma Ltd (REDIF)

Redhill Biopharma Ltd (REDIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Redhill Biopharma Ltd

Description:

RedHill Biopharma Ltd was incorporated in 2009. It is a biopharmaceutical company focused on the development and acquisition of late clinical-stage, proprietary drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. Its current pipeline of proprietary products includes: RHB-104 - an oral combination therapy for the treatment of Crohn's disease, with an ongoing Phase III study; RHB-105 - an oral combination therapy for Helicobacter pylori infection, with an ongoing Phase III study; RHB-102 - a once-daily oral pill formulation of ondansetron for the prevention of nausea and vomiting in advanced stages of development for multiple indications, including a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting; RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; MESUPRON - a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers; RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; RHB-103 - an oral thin film formulation of rizatriptan for acute migraines; RHB-101 - a once-daily oral pill formulation of the cardio drug carvedilol.

Key Statistics

Overview:

Annual Sales, $ 0 K
Annual Net Income, $ 0 K

Growth:

1-Year Return 0.00%
3-Year Return 0.00%
5-Year Return 0.00%

Per-Share Information:

Latest Earnings Date N/A
Dividend Payout Ratio 0.00%

REDIF Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % N/A
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share N/A
Interest Coverage N/A
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar